We compound semaglutide, tirzepatide, and other GLP-1 agonist medications based on your provider's prescription
Ipamorelin works by simulating the function of particular hormones and molecules, which then prompt the body to produce and distribute endogenously-produced GH [3]
Accessibility Challenges with Prescription Options Despite their proven effectiveness, prescription GLP 1 drugs face several barriers that limit patient access: Cost considerations : Monthly expenses can range from $800-$1,200 without insurance coverage, making them unaffordable for many individuals
However, only the following three are currently approved by the FDA for use as weight-loss drugs: Semaglutide (Wegovy) Type: injectable Frequency: weekly Starting dose: 0.25 to 1.7 mg for the first 16 weeks Maintenance dose: 2.4 mg Efficacy findings: Manufacturer-sponsored studies of 803 and 1,961 people: average decrease in body weight of 7.9% and 14.9%, respectively, with smaller waists and lower total cholesterol levels, systolic blood pressure, and triglycerides Research review in 2021: weekly dose of Wegovy led to weight reduction effects in multiple studies Liraglutide (Saxenda) Type: injectable Frequency: daily Starting dose: 0.6 mg/day (with weekly increases) Maintenance dose: 3 mg/day Eligibility: Obese adults and obese children older than 12 years Efficacy findings: 2021 study of 169 people with obesity : 62.1% lost at least 5% of their body weight over 6 months and 17.2% lost at least 10% of their body weight 2021 manufacturer-sponsored study of 277 people : 9-lb weight loss over 7 months 2022 study comparing Wegovy and Saxenda in 338 people : Wegovy caused more weight after 68 weeks due to decreased hunger and food cravings Tirzepatide (Zepbound) Dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist Type: injectable Frequency: weekly Starting dose: 2.5 mg in 0.5-mL liquid solution for the first 4 weeks Maintenance dose: 5, 7.5, 10, 12.5, or 15 mg from week 5 (based on treatment response and drug tolerance) Efficacy findings: Manufactured-sponsored SURMOUNT-3 trial: total mean weight loss of 26.6% over 84 weeks Manufactured-sponsored SURMOUNT-4 trial: total mean weight loss of 26% over 88 weeks 3
Placenta 57, 329
Antidiuretics : DDAVP (Desmopressin acetate
